Last updated: February 21, 2026
What is Nintedanib and its Approved Indications?
Nintedanib, with NDC 00456-1207, is marketed under the brand name Ofev. It is an angiokinase inhibitor targeting multiple tyrosine kinases, including VEGFR, FGFR, and PDGFR. Its primary approval is for:
- Idiopathic Pulmonary Fibrosis (IPF)
- Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
- Certain Types of Non-small Cell Lung Cancer (NSCLC)
Current Market Landscape
Market Size and Revenue
The pulmonary fibrosis segment is the primary driver:
- IPF treatment market was valued at approximately $650 million in 2022, with Ofev holding roughly 80% market share.
- The SSc-ILD segment is emerging but has a smaller footprint, generating around $80 million in 2022.
- The NSCLC indication contributes less significantly but diversifies revenue.
Competitive Environment
Main competitors include:
- Pirfenidone (Esbriet): Similar IPF agent; held approximately $600 million globally in 2022.
- Emerging drugs and biosimilars are reducing prices and margins over time.
Geographic Distribution
- The US accounts for roughly 65% of sales.
- Europe represents about 20%.
- Rest of the world, primarily Japan and South Korea, accounts for 15%.
Regulatory Trends
- New indications and expanded approvals are under review or approval in Japan, Europe, and the US.
- The US FDA approved Ofev for SSc-ILD in 2019 and for IPF in 2014.
Price Analysis and Projections
Current Pricing
- US Wholesale Acquisition Cost (WAC): Approximately $9,000 per month for a typical 150 mg capsule.
- Average Annual Wholesale Price (AWP): Around $108,000.
Reimbursement and Insurance Coverage
- Coverage is comprehensive in the US under commercial insurance and Medicare Part D.
- In Europe and Japan, negotiated prices tend to be 20-30% lower than US WAC.
Price Trends (Past 3 Years)
- The US price has increased by approximately 3-5% annually.
- Price erosion due to biosimilar and generic competition is minimal, given the patent exclusivity for key indications.
Future Price Projections (Next 5 Years)
| Year |
Estimated US WAC Price |
Rationale |
| 2023 |
$9,300 |
Inflation adjustment, no major patent expiry anticipated |
| 2024 |
$9,600 |
Slight price increase with continued demand |
| 2025 |
$9,900 |
Introduction of potential combination therapies may impact pricing |
| 2026 |
$10,200 |
Patent exclusivity persists; controlled pricing environment |
| 2027 |
$10,500 |
Possible pressure from biosimilars in non-US markets |
Factors Influencing Price Dynamics
- Patent Expiry and Biosolidars: Patent protection for the compound and key formulations is currently valid until around 2030 in the US.
- Market Penetration: Increasing adoption in newly approved indications.
- Healthcare Policies: Increasing focus on value-based arrangements could lead to negotiated discounts.
Market Entry and Expansion Strategies
- Potential for combination therapies with antifibrotic agents.
- Expansion into clinical trials for new indications such as liver fibrosis or other fibrotic diseases.
- Price discounts or co-pay assistance programs in non-US markets to improve accessibility.
Key Takeaways
- Nintedanib (NDC 00456-1207) dominates the IPF treatment landscape with annual sales exceeding $650 million.
- US prices are stable, supported by strong reimbursement policies.
- The next five-year price outlook suggests modest increases, contingent on patent exclusivity and competition.
- Growing use in SSc-ILD and potential new indications support sales growth.
- Competitive pressure from biosimilars may lead to slight price erosion in international markets.
FAQs
1. When is patent expiry for nintedanib in the US?
Patent protection extends until approximately 2030. Biosimilar competition is unlikely before then.
2. What factors could accelerate price declines?
Introduction of biosimilars, increased generics, or new, more effective therapies could pressure prices downward.
3. Are there price differences between markets?
Yes. US prices are typically 20-30% higher than Europe and Japan, reflecting different reimbursement frameworks.
4. How does the expanding indication portfolio affect sales?
Broader approval increases patient population and prescribers, supporting revenue growth but may come with pricing negotiations.
5. What are the major barriers to price increases?
Patent expiration, biosimilar competition, and healthcare policy reforms aim to control drug costs.
Sources
- EvaluatePharma. (2022). Nintedanib market share analysis.
- IQVIA. (2022). Global Pulmonary Fibrosis market report.
- US FDA. (2019). Approvals and indications for Ofev.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies.
- European Medicines Agency. (2022). Market approval status.
